Potential health hazard — use of or exposure to this product may cause temporary or medically reversible adverse health consequences.
GaviLyteTM - C PEG-3350 (240g) and Electrolytes for Oral Solution Recalled by Novel Laboratories, Inc. d.b.a LUPIN Due to Failed Stability Specification; Out of specification for Osmolarity
What You Should Do
Stop using this product immediately. Do not consume, use, or distribute it.
Return the product to the place of purchase for a full refund. If you have questions, contact Novel Laboratories, Inc. d.b.a LUPIN directly.
Affected Products
GaviLyteTM - C PEG-3350 (240g) and Electrolytes for Oral Solution, USP with Flavor Pack Manufactured by Novel Laboratories, Inc. Somerset, NJ 08873, USA Manufactured for Lupin Pharmaceuticals, Inc. Baltimore, MD 21202 NDC 43386-060-19
Quantity: 20,814 bottles
Why Was This Recalled?
Failed Stability Specification; Out of specification for Osmolarity
Where Was This Sold?
This product was distributed nationwide across all 50 states.
About Novel Laboratories, Inc. d.b.a LUPIN
Novel Laboratories, Inc. d.b.a LUPIN has 1 total recall tracked by RecallDetector.
Related Recalls
Icosapent Ethyl Capsules Recalled by Zydus Pharmaceuticals (USA) Inc Due to Failed Tablet/Capsule specifications: Red dots inside capsule and...
Zydus Pharmaceuticals (USA) Inc · March 9, 2026
Product label: Temozolomide Capsules Recalled by Rising Pharma Holding, Inc. Due to Failed Impurities/Degradation Specifications: An out-of-specification result observed during...
Rising Pharma Holding, Inc. · March 3, 2026
Semaglutide Inj. Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Tirzepatide Inj Recalled by New Life Pharma LLC Due to Lack of Assurance of Sterility
New Life Pharma LLC · February 26, 2026
Data sourced from the FDA (Drug). Last updated March 26, 2026. View original report